Market Place
Sourcing Support
All News #Library
Biotech
CASI Announces Ph1 CID103 Updates in Chronic ITP Thrombocytopenia
12 Jan 2026 //
PHARMIWEB
CASI Pharma Reveals CID-103 Itp Study Results At ASH Meeting
08 Dec 2025 //
PHARMIWEB
CASI Pharma To Join Guggenheim Healthcare Innovation Conference
04 Nov 2025 //
PHARMIWEB
CASI Pharma To Present CID-103 Clinical Results at ASH Meeting
03 Nov 2025 //
PHARMIWEB
CASI Pharma to Escalate CID-103 Dose in Phase 1 ITP Study
08 Sep 2025 //
PHARMAWEB
CASI Pharmaceuticals to Attend Cantor Global Health Conference
28 Aug 2025 //
PHARMAWEB
CASI Pharmaceuticals to Divest Assets in China
12 May 2025 //
ACCESSWIRE
CASI Doses First Patient In CID-103 Trial For Thrombocytopenia
06 Jan 2025 //
ACCESSWIRE
CASI Pharmaceuticals Receives CTA Approval for CID-103 in ITP
24 Oct 2024 //
ACCESSWIRE
CASI Pharmaceuticals To Submit IND For CID-103, Receives Acquisition Proposal
26 Jun 2024 //
PR NEWSWIRE
CASI Pharmaceuticals Receives FDA Clearance On The IND App For CID-103 In ITP
15 May 2024 //
PR NEWSWIRE
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206
05 Mar 2024 //
PR NEWSWIRE
CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA
08 Nov 2023 //
PR NEWSWIRE
BioNTech inks cancer deal with Chinese biotech; Eikon, CASI buy Cleave’ assets
20 Jul 2023 //
ENDPTS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.